NCT04353466View on ClinicalTrials.gov

Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Gaucher Disease, Type 1
Interventions
PROCEDURE

quantitative chemical shift imaging (QCSI)

"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"

DRUG

Elelyso

intravenous (IV) infusions of Elelyso

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Shaare Zedek Medical Center

OTHER

NCT04353466 - Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs | Biotech Hunter | Biotech Hunter